A Modular, Multipart, Multi-arm, Open-label, Phase I/IIa Study to Evaluate the Safety and Tolerability of EP0042 Alone and in Combination with Anti-cancer Treatments in Patients with Advanced Malignancies
Latest Information Update: 04 Feb 2025
At a glance
- Drugs EP 0042 (Primary) ; Antineoplastics
- Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; First in man
- Sponsors Ellipses Pharma
Most Recent Events
- 10 Dec 2024 Results (n=46) assessing final data from the dose escalation and optimization cohorts from a Phase I/IIa study of EP0042, presented at the 66th American Society of Hematology Annual Meeting and Exposition.
- 02 Jan 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2025.
- 02 Jan 2024 Planned primary completion date changed from 1 Sep 2023 to 1 Oct 2025.